UK markets open in 7 hours 4 minutes

Bellerophon Therapeutics, Inc. (0HMP.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
1.4364+0.0816 (+6.02%)
At close: 02:38PM BST
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) -0.08
52-week change 3N/A
S&P500 52-week change 3-15.36%
52-week high 31.4364
52-week low 31.4364
50-day moving average 3N/A
200-day moving average 3N/A

Share statistics

Avg vol (3-month) 3N/A
Avg vol (10-day) 3N/A
Shares outstanding 5N/A
Implied shares outstanding 6N/A
Float 87.31M
% held by insiders 13.52%
% held by institutions 131.76%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2021
Most-recent quarter (mrq)30 Jun 2022

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-48.51%
Return on equity (ttm)-88.03%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -21.19M
Net income avi to common (ttm)-18.65M
Diluted EPS (ttm)-1.8850
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)16.33M
Total cash per share (mrq)1.71
Total debt (mrq)586k
Total debt/equity (mrq)4.77
Current ratio (mrq)3.12
Book value per share (mrq)1.29

Cash flow statement

Operating cash flow (ttm)-17.97M
Levered free cash flow (ttm)-12.68M